耳鼻咽喉科・頭頸部外科91巻13号

2019年12月発行

特集 舌がん・口腔がん治療の最前線〔特別付録web動画〕 《治療》

口腔がんにおける化学放射線療法，術後補助療法，進行例・再発例の治療成績

著者： 山崎知子¹

所属機関： ¹宮城県立がんセンター頭頸部内科

ページ範囲：P.1151 - P.1154

POINT

●手術可能な口腔がんの標準療法は，根治切除（＋再建）である。

●リンパ節節外浸潤，原発巣の切除断端陽性で，全身状態良好例には，補助化学放射線療法としてシスプラチン同時併用化学放射線療法を施行する。

●口腔がんにおける術前化学療法，および化学放射線療法の生存率への上乗せに関するエビデンスは乏しい。

●再発・遠隔転移を有する口腔がんに全身化学療法は有用である。

参考文献

1）National Comprehensive Cancer Network：NCCN Guidelines. Head and Neck Cancers. Version Ⅰ, 2019

2）日本頭頸部癌学会（編）：頭頸部癌診療ガイドライン 2018年版．金原出版，東京，2018

3）Pignon JP, et al：Meta-analysis of chemotherapy in head and neck cancer（MACH-NC）：an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92：4-14, 2009

4）Marta GN, et al：Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients：systematic review and meta-analysis. Eur J Cancer 51：2596-2603, 2015

5）Budach W, et al：Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck（HNSCC）：a meta-analysis of randomized trials. Radiother Oncol 118：238-243, 2016

6）Blanchard P, et al：Meta-analysis of chemotherapy in head and neck cancer（MACH-NC）：a comprehensive analysis by tumour site. Radiother Oncol 100：33-40, 2011

7）Mehanna H, et al：Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer（De-ESCALaTE HPV）：an open-label randomised controlled phase 3 trial. Lancet 393：51-60, 2019

8）Cooper JS, et al：Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350：1937-1944, 2004

9）Bernier J, et al：Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350：1945-1952, 2004

10）Cooper JS, et al：Long-term follow-up of the RTOG 9501/intergroup phase Ⅲ trial：postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84：1198-1205, 2012

11）Winquist E, et al：Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck：a systematic review with meta-analysis. Head Neck 29：38-46, 2007

12）日本臨床腫瘍学会（編）：頭頸部がん薬物療法ガイダンス 第2版．金原出版，東京，2018

13）Licitra L, et al：Primary chemotherapy in resectable oral cavity squamous cell cancer：a randomized controlled trial. J Clin Oncol 21：327-333, 2003

14）Bossi P, et al：Preoperative chemotherapy in advanced resectable OCSCC：long-term results of a randomized phase Ⅲ trial. Ann Oncol 25：462-466, 2014

15）Zhong LP, et al：Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31：744-751, 2013

16）Lau A, et al：Induction chemotherapy for squamous cell carcinomas of the oral cavity：a cumulative meta-analysis. Int J Oral Maxillofac Surg 46：125-126, 2017

17）Mohr C, et al：Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective, multicentric, randomized DOSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx（a 3-year follow-up）. Int J Oral Maxillofac Surg 23：140-148, 1994

18）Klug C, et al：Preoperative radiochemotherapy and radical resection for stages Ⅱ-Ⅳ oral and oropharyngeal cancer：outcome of 222 patients. Int J Oral Maxillofac Surg 34：143-148, 2005

19）Vermorken JB, et al：Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359：1116-1127, 2008

20）Ferris RL, et al：Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375：1856-1867, 2016

21）Ferris RL, et al：Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck：2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81：45-51, 2018

22）Strome SE, et al：B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63：6501-6505, 2003

23）Badoual C, et al：PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73：128-138, 2013